Evolent Health
EVH
192 hedge funds and large institutions have $1.01B invested in Evolent Health in 2019 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 69 increasing their positions, 50 reducing their positions, and 35 closing their positions.
48% more call options, than puts
Call options by funds: $5.28M | Put options by funds: $3.56M
38% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 50
23% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 35
3% more funds holding
Funds holding: 186 → 192 (+6)
7.03% less ownership
Funds ownership: 107.89% → 100.86% (-7%)
40% less capital invested
Capital invested by funds: $1.67B → $1.01B (-$662M)
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$28.4M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$21.6M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$12.2M |
| 4 |
Two Sigma Investments
New York
|
+$12M |
| 5 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$11.4M |
Top Sellers
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$42.5M |
| 2 |
Bank of New York Mellon
New York
|
-$29.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$27.1M |
| 4 |
Millennium Management
New York
|
-$25.9M |
| 5 |
CC
Chicago Capital
Chicago,
Illinois
|
-$23.9M |
EVH Hedge Fund Activity: Q1 2019 in Review
192 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Evolent Health (EVH) for Q1 2019, worth a combined $1.01B — down 40% from $1.67B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new EVH positions and 35 closed out — a net gain of 8 holders — while 69 added to existing stakes and 50 trimmed.
The largest buyer was Credit Suisse, adding an estimated $28.4M. The largest seller was Capital Research Global Investors, cutting an estimated $42.5M.
- 192 institutional investors held Evolent Health (EVH) as of Q1 2019, up from 186 in Q4 2018.
- Funds reported $1.01B of Evolent Health stock for Q1 2019, down 40% quarter-over-quarter.
- 43 funds opened new Evolent Health positions in Q1 2019 and 35 closed out, a net change of +8 holders.
- The largest Evolent Health buyer in Q1 2019 was Credit Suisse, an estimated $28.4M added.
- The largest Evolent Health seller in Q1 2019 was Capital Research Global Investors, an estimated $42.5M sold.
Based on aggregated 13F filings for Q1 2019.